The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field

Johan van Griensven, Anja De Weiggheleire, Alexandre Delamou, Peter G Smith, Tansy Edwards, Philippe Vandekerckhove, Elhadj Ibrahima Bah, Robert Colebunders, Isola Herve, Catherine Lazaygues, Nyankoye Haba, Lutgarde Lynen, Johan van Griensven, Anja De Weiggheleire, Alexandre Delamou, Peter G Smith, Tansy Edwards, Philippe Vandekerckhove, Elhadj Ibrahima Bah, Robert Colebunders, Isola Herve, Catherine Lazaygues, Nyankoye Haba, Lutgarde Lynen

Abstract

The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, nonrandomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea, enrolled 102 patients by 7 July 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. Although no efficacy data are available yet, current field experience supports the safety, acceptability, and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from nontrial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.

Keywords: Ebola; Guinea; clinical trial; convalescent plasma; therapy.

© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.

References

    1. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695–703.
    1. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599–609.
    1. Hsu JL, Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect Dis Clin North Am 2011; 25:773–88.
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al. . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80–90.
    1. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010; 38:e66–73.
    1. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol 2015; 89:6117–20.
    1. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2:1216–7.
    1. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 1984; 44:528–33.
    1. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984; 149:420–7.
    1. McCormick JB, King IJ, Webb PA et al. . Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20–6.
    1. Frame JD, Verbrugge GP, Gill RG, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg 1984; 78:319–24.
    1. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim guidance for national health authorities and blood transfusion services. Geneva, Switzerland: WHO, 2014.
    1. World Health Organization. The clinical use of blood handbook. Geneva, Switzerland: WHO, 2002.
    1. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142:1–11.
    1. . Putative investigational therapeutics in the treatment of patients with known Ebola infection. 2015. Available at: .
    1. Qiu X, Wong G, Audet J et al. . Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47–53.
    1. Jahrling PB, Geisbert J, Swearengen JR et al. . Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135–40.
    1. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196(suppl 2):S400–3.
    1. Mupapa K, Massamba M, Kibadi K et al. . Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(suppl 1):S18–23.
    1. Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 1999; 179(suppl 1):S24–7.
    1. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541–4.
    1. Lyon GM, Mehta AK, Varkey JB et al. . Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371:2402–9.
    1. Kraft CS, Hewlett AL, Koepsell S et al. . The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015; 61:496–502.
    1. World Health Organization. Compassionate use of experimental treatments for Ebola virus disease: outcomes in 14 patients admitted from August to November, 2014. Geneva, Switzerland: WHO, 2015.
    1. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci 2014; 51:120–5.
    1. El-Ekiaby M, Vargas M, Sayed M et al. . Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. PLoS Negl Trop Dis 2015; 9:e0003501.
    1. Emergency evaluation of convalescent plasma for Ebola viral disease (EVD) in Guinea (Ebola-Tx). NCT02342171.
    1. Clinical trial to evaluate the efficacy and safety of convalescent plasma for Ebola treatment (EVD001). NCT02333578.
    1. Adebamowo C, Bah-Sow O, Binka F et al. . Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014; 384:1423–4.
    1. Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G et al. . Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015.
    1. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77:7539–44.
    1. Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology 2002; 293:15–9.
    1. Burnouf T, Emmanuel J, Mbanya D et al. . Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet 2014; 384:1347–8.
    1. Bannister-Tyrrell M, Gryseels C, Delamou A, D'Alessandro U, van GJ, Grietens KP. Blood as medicine: social meanings of blood and the success of Ebola trials. Lancet 2015; 385:420.
    1. Boahen O, Owusu-Agyei S, Febir LG et al. . Community perception and beliefs about blood draw for clinical research in Ghana. Trans R Soc Trop Med Hyg 2013; 107:261–5.
    1. Colebunders RL, Cannon RO. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis 2015; 211:1208–10.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj